Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday, July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European Time members of Cell Therapeutics, Inc.'s (CTI) management team will host a conference call to discuss today's announcement of the interim results of its phase II/III RAPID trial comparing CHOP-R to CPOP-R, in which pixantrone is substituted for doxorubicin in standard CHOP-R, in first-line treatment of patients with aggressive non-Hodgkin's lymphoma.

                           Conference Call Numbers

                              Wednesday, July 11

       1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European

                       1-800-240-7305 (US Participants)

                        1-303-262-2137 (International)


                            Live audio webcast at

                             www.cticseattle.com

                     will be archived for post listening

       approximately two hours after call ends, available for five days


     Call-back numbers for post listening available at 6:30 p.m. Eastern:

                       1-800-405-2236 (US Participants)

                        1-303-590-3000 (International)

                             Passcode: 11093505#


     Media Contact:


     Cell Therapeutics, Inc.

     Dan Eramian

     T: 206.272.4343

     C: 206.854.1200

     Susan Callahan

     T: 206.272.4472

     F: 206.272.4434

     E: 

     www.cticseattle.com/media.htm


     Investors Contact:


     Cell Therapeutics, Inc.

     Leah Grant

     T: 206.282.7100

     F: 206.272.4434

     E: 

     www.cticseattle.com/investors.htm

media@ctiseattle.com invest@ctiseattle.com

CONTACT: media, Dan Eramian, +1-206-272-4343, or cell, +1-206-854-1200, orSusan Callahan, +1-206-272-4472, or fax, +1-206-272-4434, or, or investors, Leah Grant, +1-206-282-7100, or fax,+1-206-272-4434, or , all for Cell Therapeutics, Inc. media@ctiseattle.com invest@ctiseattle.com

Web site: http://www.cticseattle.com//

Ticker Symbol: (NASDAQ-NMS:CTIC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: July 2007

View comments

Hide
(web4)